To compare idarubicin versus daunorubicin, or other anthracyclines, when used with cytosine arabinoside as induction chemotherapy for newly diagnosed acute myeloid leukaemia (AML).
Assessment of study quality
The data sets were checked centrally for internal consistency, for consistency with any previous publications, for balance between treatment groups, and for the exclusion of any randomised participants, or the inclusion of any nonrandomised participants. If there were any problems, the trialists were contacted so that errors or omissions were rectified where possible. Summary tables of information for each trial were also sent to the trialists for checking. In addition, the review was given to each trial group to ensure the results presented for their trial were correct.The authors excluded studies that began after 1 January 1993. The authors did not state how judgements of validity were made.
Data extraction
The data to be collected for each participant were agreed in consultation with the trialists. Such data included age, gender, nationality, white blood count, performance status, allocated treatment, dates of diagnosis, randomisation, complete remission, first relapse and death. The observed minus the expected number of events, and variance, were calculated for the idarubicin-allocated group within each trial either using simple contingency tables, or by the log rank
